Population pharmacokinetics and pharmacodynamics of praziquantel in Ugandan children with intestinal schistosomiasis: Higher dosages are required for maximal efficacy

mBio

Volumn 7, Issue 4, 2016, Pages

  Bustinduy, Amaya L ^a,b   Waterhouse, David ^a   De Sousa Figueiredo, Jose C ^c,d   Roberts, Stephen A ^e   Atuhaire, Aaron ^f   Van Dam, Govert J ^g   Corstjens, Paul L A M ^g   Scott, Janet T ^h   Stanton, Michelle C ^a   Kabatereine, Narcis B ^f   Ward, Stephen ^a   Hope, William W ^h   Russell Stothard, J ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c Provincial Hospital   (Angola)

^d DEPARTMENT OF LIFE SCIENCES   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f MINISTRY OF HEALTH   (Uganda)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRAZIQUANTEL; ANTHELMINTIC AGENT; PARASITE ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FECES ANALYSIS; FEMALE; HUMAN; INTESTINAL SCHISTOSOMIASIS MANSONI; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PARASITE LOAD; PHARMACODYNAMICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SCHOOL CHILD; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; UGANDAN; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION; ANIMAL; BLOOD; DRUG EFFECTS; FECES; PARASITE IDENTIFICATION; PARASITOLOGY; UGANDA; URINE;

ANIMALS; ANTHELMINTICS; ANTIGENS, HELMINTH; CHILD; CHILD, PRESCHOOL; FECES; FEMALE; HUMANS; MALE; PARASITE EGG COUNT; PRAZIQUANTEL; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; UGANDA;

EID: 84986584142     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00227-16     Document Type: Article

References (40)

1. Doenhoff MJ, Cioli D, Utzinger J 2008. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21:659-667. http://dx.doi.org/10.1097/QCO.0b013e328318978f
2. Colley DG, Bustinduy AL, Secor WE, King CH 2014. Human schistosomiasis. Lancet 383:2253-2264. http://dx.doi.org/10.1016/S0140-6736(13)61949-2
3. World Health Organization 2013. Assessing the efficacy of anthelmintic drug against schistosomiasis and soil-transmitted helminthiases. World Health Organization, Geneva, Switzerland
4. Mandour ME, el Turabi H, Homeida MM, el Sadig T, Ali HM, Bennett JL, Leahey WJ, Harron DW 1990. Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Trans R Soc Trop Med Hyg 84:389-393. http://dx.doi.org/10.1016/0035-9203(90)90333-A
5. Olliaro P, Delgado-Romero P, Keiser J 2014. The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). J Antimicrob Chemother 69:863-870. http://dx.doi.org/10.1093/jac/dkt491
6. World Health Organization 2006. Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. World Health Organization, Geneva, Switzerland
7. Gönnert R, Andrews P 1977. Praziquantel, a new board-spectrum antischistosomal agent. Z Parasitenkd 52:129-150. http://dx.doi.org/10.1007/BF00389899
8. Brindley PJ, Sher A 1987. The chemotherapeutic effect of praziquantel against Schistosoma mansoni is dependent on host antibody response. J Immunol 139:215-220
9. Coulibaly JT, N’Gbesso YK, Knopp S, N’Guessan NA, Silué KD, van Dam GJ, N’Goran EK, Utzinger J 2013. Accuracy of urine circulating cathodic antigen test for the diagnosis of Schistosoma mansoni in preschool-aged children before and after treatment. PLoS Negl Trop Dis 7:e2109. http://dx.doi.org/10.1371/journal.pntd.0002109
10. van Dam GJ, de Dood CJ, Lewis M, Deelder AM, van Lieshout L, Tanke HJ, van Rooyen LH, Corstjens PL 2013. A robust dry reagent lateral flow assay for diagnosis of active schistosomiasis by detection of Schistosoma circulating anodic antigen. Exp Parasitol 135:274-282. http://dx.doi.org/10.1016/j.exppara.2013.06.017
11. Mutapi F, Rujeni N, Bourke C, Mitchell K, Appleby L, Nausch N, Midzi N, Mduluza T 2011. Schistosoma haematobium treatment in 1-5 year old children: safety and efficacy of the antihelminthic drug praziquantel. PLoS Negl Trop Dis 5:e1143. http://dx.doi.org/10.1371/journal.pntd.0001143
12. Metwally A, Bennett J, Botros S, Ebeid F, El Attar G-ED 1995. Impact of drug dosage and brand on bioavailability and efficacy of praziquantel. Pharmacol Res 31:53-59. http://dx.doi.org/10.1016/1043-6618(95)80048-4
13. Irie Y, Utsunomiya H, Tanaka M, Ohmae H, Nara T, Yasuraoka K 1989. Schistosoma japonicum and S. mansoni: ultrastructural damage in the tegument and reproductive organs after treatment with levo-and dextro-praziquantel. Am J Trop Med Hyg 41:204-211
14. Tanaka M, Ohmae H, Utsunomiya H, Nara T, Irie Y, Yasuraoka K 1989. A comparison of the antischistosomal effect of levo-and dextropraziquantel on Schistosoma japonicum and S. mansoni in mice. Am J Trop Med Hyg 41:198-203
15. Meister I, Ingram-Sieber K, Cowan N, Todd M, Robertson MN, Meli C, Patra M, Gasser G, Keiser J 2014. Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni. Antimicrob Agents Chemother 58:5466-5472. http://dx.doi.org/10.1128/AAC.02741-14
16. Liu YH, Qian MX, Wang XG, Quan YZ, Yan SH, Chen BY, Li JS, Qiu ZY 1993. Levo-praziquantel versus praziquantel in experimental and clinical treatment of schistosomiasis japonica. Chin Med J 106:593-596
17. Liu YH, Qian MX, Wang XG, Jia J, Wang QN, Jiang YF, Wang RQ, Yan SH, Chen BY, Li JS 1986. Comparative efficacy of praziquantel and its optic isomers in experimental therapy of schistosomiasis japonica in rabbits. Chinese Med J 99:935-940
18. Wu MH, Wei CC, Xu ZY, Yuan HC, Lian WN, Yang QJ, Chen M, Wang CZ, Zhang ZJ, Liu ZD 1991. Comparative efficacy of levopraziquantel and praziquantel in treatment of schistosomiasis japonica at a single dose. Chin Med J 104:732-735
19. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN 2006. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 45:1077-1097. http://dx.doi.org/10.2165/00003088-200645110-00003
20. el Guiniady MA, el Touny MA, Abdel-Bary MA, Abdel-Fatah SA, Metwally A 1994. Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure. Am J Trop Med Hyg 51:809-818
21. Poole H, Terlouw DJ, Naunje A, Mzembe K, Stanton M, Betson M, Lalloo DG, Stothard JR 2014. Schistosomiasis in pre-school-age children and their mothers in Chikhwawa district, Malawi with notes on characterization of schistosomes and snails. Parasit Vectors 7:153. http://dx.doi.org/10.1186/1756-3305-7-153
22. Odogwu SE, Ramamurthy NK, Kabatereine NB, Kazibwe F, Tukahebwa E, Webster JP, Fenwick A, Stothard JR 2006. Schistosoma mansoni in infants (aged _ 3 years) along the Ugandan shoreline of Lake Victoria. Ann Trop Med Parasitol 100:315-326. http://dx.doi.org/10.1179/136485906X105552
23. Bosompem KM, Bentum IA, Otchere J, Anyan WK, Brown CA, Osada Y, Takeo S, Kojima S, Ohta N 2004. Infant schistosomiasis in Ghana: a survey in an irrigation community. Trop Med Int Health 9:917-922. http://dx.doi.org/10.1111/j.1365-3156.2004.01282.x
24. Sousa-Figueiredo JC, Betson M, Atuhaire A, Arinaitwe M, Navaratnam AM, Kabatereine NB, Bickle Q, Stothard JR 2012. Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children. PLoS Negl Trop Dis 6:e1864. http://dx.doi.org/10.1371/journal.pntd.0001864
25. Leopold G, Ungethüm W, Groll E, Diekmann HW, Nowak H, Wegner DH 1978. Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics. Eur J Clin Pharmacol 14:281-291. http://dx.doi.org/10.1007/BF00560463
26. World Health Organization 2011. Report of a meeting to review the results of studies on the treatment of schistosomiasis in preschool-age children. World Health Organization, Geneva, Switzerland
27. Xiao SH, Catto BA 1989. Comparative in vitro and in vivo activity of racemic praziquantel and its levorotated isomer on Schistosoma mansoni. J Infect Dis 159:589-592. http://dx.doi.org/10.1093/infdis/159.3.589
28. Wu MH, Wei CC, Xu ZY, Yuan HC, Lian WN, Yang QJ, Chen M, Jiang QW, Wang CZ, Zhang SJ 1991. Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isomer praziquantel in 278 cases of schistosomiasis japonica.AmJ Trop Med Hyg 45:345-349
29. Godawska-Matysik A, Kieć-Kononowicz K 2006. Biotransformation of praziquantel by human cytochrome P450 3A4 (CYP 3A4). Acta Pol Pharm 63:381-385
30. Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, Zaya MJ 2003. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 307:573-582. http://dx.doi.org/10.1124/jpet.103.054841
31. Becker B, Mehlhorn H, Andrews P, Thomas H, Eckert J 1980. Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro. Z Parasitenkd 63:113-128. http://dx.doi.org/10.1007/BF00927527
32. Danso-Appiah A, Olliaro PL, Donegan S, Sinclair D, Utzinger J 2013. Drugs for treating Schistosoma mansoni infection. Cochrane Database Syst Rev 2013(2):CD000528. http://dx.doi.org/10.1002/14651858.CD000528.pub2
33. Danso-Appiah A, Utzinger J, Liu J, Olliaro P 2008. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev 2008(3):CD000053. http://dx.doi.org/10.1002/14651858.CD000053.pub2
34. Olliaro PL, Vaillant MT, Belizario VJ, Lwambo NJ, Ouldabdallahi M, Pieri OS, Amarillo ML, Kaatano GM, Diaw M, Domingues AC, Favre TC, Lapujade O, Alves F, Chitsulo L 2011. A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Negl Trop Dis 5:e1165. http://dx.doi.org/10.1371/journal.pntd.0001165
35. Sousa-Figueiredo JC, Betson M, Kabatereine NB, Stothard JR 2013. The urine circulating cathodic antigen (CCA) dipstick: a valid substitute for microscopy for mapping and point-of-care diagnosis of intestinal schistosomiasis. PLoS Negl Trop Dis 7:e2008. http://dx.doi.org/10.1371/journal.pntd.0002008
36. Sousa-Figueiredo JC, Pleasant J, Day M, Betson M, Rollinson D, Montresor A, Kazibwe F, Kabatereine NB, Stothard JR 2010. Treatment of intestinal schistosomiasis in Ugandan preschool children: best diagnosis, treatment efficacy and side-effects, and an extended praziquantel dosing pole. Int Health 2:103-113. http://dx.doi.org/10.1016/j.inhe.2010.02.003
37. Katz N, Chaves A, Pellegrino J 1972. A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 14:397-400
38. van Etten L, Folman CC, Eggelte TA, Kremsner PG, Deelder AM 1994. Rapid diagnosis of schistosomiasis by antigen detection in urine with a reagent strip. J Clin Microbiol 32:2404-2406
39. Lima RM, Ferreira MA, Ponte TM, Marques MP, Takayanagui OM, Garcia HH, Coelho EB, Bonato PS, Lanchote VL 2009. Enantioselective analysis of praziquantel and trans-4-hydroxypraziquantel in human plasma by chiral LC-MS/MS: application to pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci 877:3083-3088. http://dx.doi.org/10.1016/j.jchromb.2009.07.036
40. D’Argenio DZ, Schumitzky A, Wang X 2009. ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.